Bavarian Nordic A/S is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora and Vivotif.
1994
1.4K+
LTM Revenue $795M
LTM EBITDA $223M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bavarian Nordic has a last 12-month revenue of $795M and a last 12-month EBITDA of $223M.
In the most recent fiscal year, Bavarian Nordic achieved revenue of $987M and an EBITDA of $299M.
Bavarian Nordic expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Bavarian Nordic valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $440M | $987M | $781M | $795M | XXX |
Gross Profit | $79.7M | $238M | $643M | XXX | XXX |
Gross Margin | 18% | 24% | 82% | XXX | XXX |
EBITDA | $26.2M | $299M | $211M | $223M | XXX |
EBITDA Margin | 6% | 30% | 27% | 28% | XXX |
Net Profit | -$64.9M | -$48.5M | $206M | XXX | XXX |
Net Margin | -15% | -5% | 26% | XXX | XXX |
Net Debt | $64.5M | $156M | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 7, 2025, Bavarian Nordic's stock price is DKK 175 (or $25).
Bavarian Nordic has current market cap of DKK 13.6B (or $1.9B), and EV of DKK 11.9B (or $1.7B).
See Bavarian Nordic trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.7B | $1.9B | XXX | XXX | XXX | XXX | $1.77 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 7, 2025, Bavarian Nordic has market cap of $1.9B and EV of $1.7B.
Bavarian Nordic's trades at 2.1x LTM EV/Revenue multiple, and 7.4x LTM EBITDA.
Analysts estimate Bavarian Nordic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bavarian Nordic and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $1.7B | XXX | XXX | XXX |
EV/Revenue | 2.1x | XXX | XXX | XXX |
EV/EBITDA | 7.9x | XXX | XXX | XXX |
P/E | 16.7x | XXX | XXX | XXX |
P/E/Growth | 2.1x | XXX | XXX | XXX |
EV/FCF | 20.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBavarian Nordic's NTM/LTM revenue growth is 12%
Bavarian Nordic's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Bavarian Nordic's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bavarian Nordic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bavarian Nordic and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -21% | XXX | XXX | XXX | XXX |
EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
EBITDA Growth | -29% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 39% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 32% | XXX | XXX | XXX | XXX |
Opex to Revenue | 44% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
CSL | XXX | XXX | XXX | XXX | XXX | XXX |
Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bavarian Nordic acquired XXX companies to date.
Last acquisition by Bavarian Nordic was XXXXXXXX, XXXXX XXXXX XXXXXX . Bavarian Nordic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Bavarian Nordic founded? | Bavarian Nordic was founded in 1994. |
Where is Bavarian Nordic headquartered? | Bavarian Nordic is headquartered in Denmark. |
How many employees does Bavarian Nordic have? | As of today, Bavarian Nordic has 1.4K+ employees. |
Who is the CEO of Bavarian Nordic? | Bavarian Nordic's CEO is Mr. Paul Chaplin. |
Is Bavarian Nordic publicy listed? | Yes, Bavarian Nordic is a public company listed on CSE. |
What is the stock symbol of Bavarian Nordic? | Bavarian Nordic trades under BAVA ticker. |
When did Bavarian Nordic go public? | Bavarian Nordic went public in 1998. |
Who are competitors of Bavarian Nordic? | Similar companies to Bavarian Nordic include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
What is the current market cap of Bavarian Nordic? | Bavarian Nordic's current market cap is $1.9B |
What is the current revenue of Bavarian Nordic? | Bavarian Nordic's last 12-month revenue is $795M. |
What is the current EBITDA of Bavarian Nordic? | Bavarian Nordic's last 12-month EBITDA is $223M. |
What is the current EV/Revenue multiple of Bavarian Nordic? | Current revenue multiple of Bavarian Nordic is 2.1x. |
What is the current EV/EBITDA multiple of Bavarian Nordic? | Current EBITDA multiple of Bavarian Nordic is 7.4x. |
What is the current revenue growth of Bavarian Nordic? | Bavarian Nordic revenue growth between 2023 and 2024 was -21%. |
Is Bavarian Nordic profitable? | Yes, Bavarian Nordic is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.